MetaCap

Ardelyx (ARDX) vs Oric Pharmaceuticals (ORIC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oric Pharmaceuticals (ORIC) has outperformed Ardelyx (ARDX) over the past year, losing 36.7% versus a loss of 44.8%. Over five years, ARDX leads with a +234.8% price change compared with -48.6% for ORIC. Oric Pharmaceuticals is the larger company by market cap ($764.9 million vs $751.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARDX-44.83%ORIC-36.66%
+52%+0%-52%
Nov 21, 20251 yearNov 20, 2026
ARDX+199.00%ORIC-55.39%
+922%+394%-133%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARDX versus ORIC key metrics
MetricARDXORIC
Share price$2.99$7.36
Market cap$751.60M$764.94M
1-day change-2.29%-4.42%
YTD return-48.71%-10.02%
1-year return-44.83%-36.66%
5-year return+234.83%-48.64%
Forward P/E18.92—
EPS (TTM)$-0.23$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$407.32M—
Revenue growth (YoY)+22.09%—
Net income (latest FY)$-61.60M$-129.47M
Gross margin90.29%—
Operating margin-10.06%—
Net margin-15.12%—
52-week high$8.40$14.68
52-week low$2.80$7.23
Distance from 52-week high-64.40%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+318.06%+194.97%
Average volume4.46M1.59M
Shares outstanding251.37M103.93M
Employees489111
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Ardelyx

ARDX stock →

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 489 employees

About Oric Pharmaceuticals

ORIC stock →

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.

Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees

ARDX vs ORIC FAQ

Which is bigger, Ardelyx or Oric Pharmaceuticals?

Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $764.94M compared with $751.60M for Ardelyx (ARDX).

Which stock has performed better over the past year, ARDX or ORIC?

ORIC returned -36.66% over the past 12 months, compared with -44.83% for ARDX (price return, excluding dividends). Past performance does not predict future results.

Are Ardelyx and Oric Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons